A month after filing a new drug application for Treanda in chronic lymphocytic leukemia, Cephalon Inc. said the drug met its endpoint in a pivotal trial in indolent non-Hodgkin's lymphoma patients who are refractory to rituximab. (BioWorld Today)
SAN DIEGO - Chances are the biotech community in Southern California is not reading this article. More likely, they are still glued to their TV sets, trying to determine whether or not their homes are safe, as they have since the fires began. (BioWorld Today)
Under-a-dollar shares of DOR BioPharma Inc. lost more than half their value after the FDA issued a not approvable letter for orBec, a steroid-sparing agent, citing the need for further efficacy and safety data in patients with gastrointestinal graft-vs.-host disease, a complication of hematopoietic cell transplantation. (BioWorld Today)
Under-a-dollar shares of DOR BioPharma Inc. lost more than half their value after the FDA issued a not approvable letter for orBec, a steroid-sparing agent, citing the need for further efficacy and safety data in patients with gastrointestinal graft-vs.-host disease, a complication of hematopoietic cell transplantation. (BioWorld Today)
A month after sealing a joint venture deal focused on microRNA, Isis Pharmaceuticals Inc. continues to capitalize on its growing antisense platform by licensing rights to an inhaled asthma product to newly formed Altair Therapeutics Inc. (BioWorld Today)
A month after sealing a joint venture deal focused on microRNA, Isis Pharmaceuticals Inc. continues to capitalize on its growing antisense platform by licensing rights to an inhaled asthma product to newly formed Altair Therapeutics Inc. (BioWorld Today)
